Valuation: BioNTech SE

Market Cap 20.8B 23.77B 19.17B 17.77B 33.73B 2,256B 34.28B 230B 89.4B 1,113B 89.25B 87.32B 3,849B P/E 2026 *
-18.7x
P/E 2027 * -18.4x
Enterprise Value 9.95B 11.37B 9.17B 8.5B 16.14B 1,079B 16.4B 110B 42.76B 533B 42.69B 41.77B 1,841B EV / Sales 2026 *
4.59x
EV / Sales 2027 * 5.17x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week-0.61%
Current month+0.61%
1 month+6.98%
3 months+3.54%
6 months-2.09%
Current year+0.86%
1 week 81
Extreme 81
86.15
1 month 73.2
Extreme 73.2
86.15
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
397
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 31/12/2017
Chief Executive Officer 60 01/06/2008
Director of Finance/CFO - 30/06/2025
Director TitleAgeSince
Chairman 55 01/06/2008
Director/Board Member 69 01/06/2008
Director/Board Member 65 31/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%-0.61%-12.81%-15.81% 23.75B
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.78%+5.82%+16.37%+468.10% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.81%+4.43%+28.67%+194.25% 13.96B
+2.80%+2.12%+89.62%+150.22% 12.21B
Average +0.63%+5.64%+59.72%+150.06% 25.78B
Weighted average by Cap. -0.33%+3.56%+59.54%+139.36%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 2B 1.85B 3.51B 235B 3.57B 23.93B 9.31B 116B 9.29B 9.09B 401B 2.23B 2.55B 2.06B 1.91B 3.62B 242B 3.68B 24.65B 9.59B 119B 9.57B 9.36B 413B
Net income -1.05B -1.2B -968M -898M -1.7B -114B -1.73B -11.61B -4.52B -56.25B -4.51B -4.41B -194B -1.17B -1.33B -1.07B -995M -1.89B -126B -1.92B -12.88B -5.01B -62.38B -5B -4.89B -216B
Net Debt -10.85B -12.4B -10B -9.27B -17.6B -1,177B -17.88B -120B -46.64B -581B -46.56B -45.55B -2,008B -9.28B -10.61B -8.55B -7.93B -15.05B -1,007B -15.29B -103B -39.88B -497B -39.82B -38.95B -1,717B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
07/07/26 82.60 +0.73%
06/07/26 €82.00 -2.61%
03/07/26 €84.20 -1.64%
02/07/26 €85.60 +3.32%
01/07/26 €82.85 +1.66%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.26EUR
Average target price
106.82EUR
Spread / Average Target
+29.85%

Quarterly revenue - Rate of surprise